# Adimab

> Adimab is a private biotechnology company founded in 2007, headquartered in Lebanon, New Hampshire, with a west coast office in Mountain View, California. It runs a proprietary yeast-based antibody discovery and engineering platform that combines fully human synthetic and immune libraries to generate specific, stable and developable IgGs, heavy-chain antibodies (HCAbs), multispecifics, T-cell engagers and T-cell receptors. Adimab keeps no internal therapeutic pipeline and instead partners with biopharma companies through funded discovery, platform transfer and non-exclusive program deals.

Generated by the API Evangelist enrichment pipeline from apis.yml on 2026-08-02.
Method: generated (Adimab publishes no llms.txt of its own — https://adimab.com/llms.txt returns 404).

## API surface

Adimab publishes **no public developer API**. As of 2026-08-02 there is no developer
portal, no API documentation, no OpenAPI/Swagger/AsyncAPI/GraphQL contract, no SDK on
npm/PyPI/RubyGems/crates.io, no MCP server, no A2A agent card, and no /.well-known
discovery surface on adimab.com or www.adimab.com. Its capabilities are delivered as
laboratory discovery services and licensed platform transfer under partnership
agreements, not as a callable interface.

## Capabilities

- [Our Technology](https://adimab.com/capabilities/): overview of the discovery and engineering suite
- [Antibody Discovery](https://adimab.com/capabilities/discovery/): yeast-based synthetic and immune library discovery
- [Antibody Engineering](https://adimab.com/capabilities/antibody-engineering/): affinity maturation, developability and optimization
- [Multispecifics](https://adimab.com/capabilities/multispecifics/): bispecific and multispecific formats, T-cell engagers
- [Protein Engineering](https://adimab.com/capabilities/protein-engineering/): broader therapeutic protein engineering

## Partnering

- [Partnering overview](https://adimab.com/partnering/)
- [Funded discovery](https://adimab.com/partnering/funded-discovery/)
- [Platform transfer](https://adimab.com/partnering/platform-transfer/)
- [Non-exclusive programs](https://adimab.com/partnering/nonexclusive-programs/)

## Company

- [About Adimab](https://adimab.com/about-us/)
- [Leadership](https://adimab.com/leadership/)
- [Board of directors](https://adimab.com/board-of-directors/)
- [Careers](https://adimab.com/careers/open-positions/)
- [Contact](https://adimab.com/contact-us/)
- [LinkedIn](https://www.linkedin.com/company/adimab-llc/)

## Resources

- [Resources library](https://adimab.com/resources/)
- [Publications](https://adimab.com/resources/?_resources_type=publications)
- [White papers](https://adimab.com/resources/?_resources_type=white-papers)
- [Posters](https://adimab.com/resources/?_resources_type=posters)
- [Press releases](https://adimab.com/news-events/press-releases/)
- [Events](https://adimab.com/news-events/events/)

## Legal

- [Privacy policy](https://adimab.com/privacy-policy/)
- [Terms of use](https://adimab.com/terms-of-use/)

## API Evangelist artifacts

- [apis.yml](https://raw.githubusercontent.com/api-evangelist/adimab/refs/heads/main/apis.yml)
- [Domain security probe](https://raw.githubusercontent.com/api-evangelist/adimab/refs/heads/main/security/adimab-domain-security.yml)
- [Well-known probe record](https://raw.githubusercontent.com/api-evangelist/adimab/refs/heads/main/well-known/adimab-well-known.yml)